Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTRS Viatris Inc.

盘后交易 10-16 16:19:48 EDT

18.66

+0.44

+2.39%

盘后18.08

-0.58-3.08%

16:15 EDT

最高18.67	最低18.15	成交量940.75万
今开18.20	昨收18.22	日振幅2.83%
总市值214.35亿	流通市值213.23亿	总股本11.49亿
成交额1.74亿	换手率0.82%	流通股本11.43亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTRS","market":"US","secType":"STK","nameCN":"Viatris Inc.","latestPrice":18.655,"timestamp":1792180800000,"preClose":18.22,"halted":0,"volume":9407526,"hourTrading":{"tag":"盘后","latestPrice":18.08,"preClose":18.655,"latestTime":"16:15 EDT","volume":231774,"amount":4323426.671394,"timestamp":1792181743053,"change":-0.575,"changeRate":-0.030823,"amplitude":0.031091},"delay":0,"changeRate":0.02387486278814502,"floatShares":1143000000,"shares":1149000000,"eps":-0.354341,"marketStatus":"盘后交易","change":0.435,"latestTime":"10-16 16:19:48 EDT","open":18.2,"high":18.665,"low":18.15,"amount":174015721.592526,"amplitude":0.028266,"askPrice":18.66,"askSize":2,"bidPrice":17.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.354341,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792195200000},"marketStatusCode":4,"adr":0,"listingDate":1605157200000,"exchange":"NASDAQ","adjPreClose":18.22,"dividendRate":0.02573,"preHourTrading":{"tag":"盘前","latestPrice":18.28,"preClose":18.22,"latestTime":"09:29 EDT","volume":5085,"amount":92751.7221,"timestamp":1792157399999,"change":0.06,"changeRate":0.003293,"amplitude":0.01427},"postHourTrading":{"tag":"盘后","latestPrice":18.08,"preClose":18.655,"latestTime":"16:15 EDT","volume":231774,"amount":4323426.671394,"timestamp":1792181743053,"change":-0.575,"changeRate":-0.030823,"amplitude":0.031091},"volumeRatio":1.14733,"impliedVol":0.4056,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/VTRS/wiki","defaultTab":"wiki","newsList":[{"id":"1134733225","title":"Shield Therapeutics宣布全面接管ACCRUFeR美国商业化运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1134733225","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134733225?lang=zh_cn&edition=full","pubTime":"2026-08-27 23:37","pubTimestamp":1787845053,"startTime":"0","endTime":"0","summary":"路透社8月27日消息——Shield Therapeutics PLC于当日发布重大声明，透露其即将全面接管ACCRUFeR在美国市场的商业运营权，预计交割日期定于2026年9月30日。据悉，该公司已与Viatris Inc.达成一项重要协议。值得关注的是，这笔交易中Shield无需向Viatris支付任何前期款项。Shield Therapeutics进一步表示，此项交易将立即为公司带来增值效应。本次协议标志着Shield Therapeutics在美国市场战略布局的关键一步，展现了公司对其核心产品ACCRUFeR商业潜力的坚定信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2087621335.USD","BK4588","VTRS","BK4583","LU1839511570.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122412008","title":"异动解读 | Viatris盘中大跌5.04%，Q2业绩超预期但遭遇利好兑现获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1122412008","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122412008?lang=zh_cn&edition=full","pubTime":"2026-08-07 01:22","pubTimestamp":1786036952,"startTime":"0","endTime":"0","summary":"Viatris Inc.今日盘中大幅下挫5.04%，引发市场广泛关注。尽管财报数据表现亮眼，但股价在盘前短暂上涨1.08%后迅速转跌，呈现典型的“利好兑现”后获利回吐走势。公司此前已连续三个季度业绩超预期，叠加年内股价自低位已有显著涨幅，市场选择在业绩兑现节点锁定收益，导致盘中跌幅持续扩大。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128204486","title":"异动解读｜Viatris盘中下跌5.01%，Q2业绩超预期但遭获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1128204486","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128204486?lang=zh_cn&edition=full","pubTime":"2026-08-07 01:21","pubTimestamp":1786036896,"startTime":"0","endTime":"0","summary":"8月6日，Viatris盘中下跌5.01%，报16.765美元/股，成交额1.39亿美元。消息面上，公司当日盘前公布Q2财报：调整后每股收益0.69美元，超出市场预期的0.60美元达15%；营收37.56亿美元，高于预期的36.75亿美元。尽管业绩全面超预期且指引上调，但股价在盘前短暂上涨1.08%后迅速转跌，呈现典型的利好兑现后获利回吐走势。公司此前已连续三个季度超预期，叠加年内股价自低位已有显著涨幅，市场选择在业绩兑现节点锁定收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133818177","title":"特朗普药品关税计划引发关注：药价、药企与供应链将受何影响？","url":"https://stock-news.laohu8.com/highlight/detail?id=1133818177","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133818177?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:56","pubTimestamp":1784732210,"startTime":"0","endTime":"0","summary":"特朗普拟对进口仿制药实施最高200%的关税，引发市场对药价上涨、供应链重构及药企盈利的担忧。业内人士认为，两年缓冲期为企业调整产能提供了窗口，但政策细则仍待明确，最终影响将取决于关税实施范围及美国本土制造认定标准，不同药企面临的冲击或将明显分化。","market":"us","thumbnail":"https://static.tigerbbs.com/556186869d2b495debe9035461bacadc","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/556186869d2b495debe9035461bacadc"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"特朗普药品关税计划引发关注：药价、药企与供应链将受何影响？","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA","VTRS","AMPH","ANIP"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1105720351","title":"Viatris公布Vr-205治疗日本成人原发性免疫球蛋白A肾病三期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1105720351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105720351?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:59","pubTimestamp":1782730767,"startTime":"0","endTime":"0","summary":"Viatris Inc. 近日宣布，其候选药物Vr-205在日本成人原发性免疫球蛋白A肾病患者中开展的三期临床研究，已获得积极的顶线结果。该研究达到了预设的主要终点，数据表明Vr-205在目标患者群体中展现出良好的疗效与安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VTRS","LU1839511570.USD","LU2087621335.USD","BK4585","BK4588","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114542416","title":"澳大利亚TGA：Viatris将继续在澳获得所有规格Creon的常规供应；供应量可能受限","url":"https://stock-news.laohu8.com/highlight/detail?id=1114542416","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114542416?lang=zh_cn&edition=full","pubTime":"2026-06-11 14:28","pubTimestamp":1781159299,"startTime":"0","endTime":"0","summary":"澳大利亚药品管理局（TGA）确认，Viatris Inc. 将继续在澳大利亚市场获得其所有规格的Creon胰酶制剂的常规供应。\n然而，该监管机构同时指出，这些产品的供应量在未来一段时间内可能受到限制，存在供应紧张的可能性。Viatris公司作为Creon在澳大利亚的供应商，将继续维持其供应链的运转。\nTGA的声明旨在缓解市场对Creon可能断供的担忧，同时提示医疗专业人员和患者，在获取某些规格的药品时可能会遇到延迟或数量限制的情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4585","BK4583","LU2087621335.USD","BK4588","BK4007","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151742930","title":"澳大利亚TGA：全球需求意外激增，导致Creon胰酶制剂供应受限","url":"https://stock-news.laohu8.com/highlight/detail?id=1151742930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151742930?lang=zh_cn&edition=full","pubTime":"2026-06-11 14:28","pubTimestamp":1781159299,"startTime":"0","endTime":"0","summary":"澳大利亚治疗商品管理局（TGA）发布通告称，由于全球范围内对Creon胰酶制剂的需求出现意外增长，目前该药品的供应正面临限制。\n这一供应紧张局面源于市场需求超出预期，导致生产与分销环节出现瓶颈。相关药品的供应保障工作正面临挑战。\n作为Creon的制造商之一，Viatris Inc. 的供应情况可能因此受到影响。目前，监管机构与相关企业正密切关注事态发展，并努力协调以缓解供应压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2087621335.USD","BK4588","VTRS","BK4583","LU1839511570.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193216760","title":"异动解读 | 业绩超预期叠加中国业务强劲，Viatris盘前大涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193216760","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193216760?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:29","pubTimestamp":1778164162,"startTime":"0","endTime":"0","summary":"Viatris Inc. (VTRS) 今日盘前股价大幅上涨5.27%，表现亮眼。消息面上，公司公布的第一季度业绩超出市场预期，营收和利润均超分析师预估。这主要得益于其在中国市场的强劲表现以及品牌药品（如立普妥、诺瓦斯克）销售的旺盛需求。此外，公司高管在近期电话会议中透露，对2026年大中华区业务发展持乐观态度，预计该市场营收将实现中高个位数增长，进一步增强了市场信心。公司不仅重申了2026年的盈利和营收预测，其在中国及多个新兴市场的增长也超出了预期，展现了公司核心业务的稳定性与增长潜力。这些积极因素共同推动了股价在盘前交易时段的大幅上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129013509","title":"Viatris高管预计2026年大中华区营收将实现中高个位数增长——电话会议透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1129013509","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129013509?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:55","pubTimestamp":1778158542,"startTime":"0","endTime":"0","summary":"Viatris公司高管在近期电话会议中透露，集团对2026年大中华区业务发展持乐观态度，预计该市场营收将呈现中高个位数的增长态势。这一预测彰显了公司对亚太区域战略布局的信心，同时也反映出中国医药市场持续释放的增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4588","LU2087621335.USD","BK4007","BK4583","LU1839511570.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120683557","title":"财报前瞻｜Viatris Inc.本季度营收预计增3.77%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1120683557","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120683557?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:29","pubTimestamp":1777519786,"startTime":"0","endTime":"0","summary":"Viatris Inc.将于2026年05月07日盘前发布最新季度财报，市场预期关注收入与每股收益的同比变化及全年指引兑现度。市场一致预期本季度收入为33.57亿美元，同比增长3.77%；调整后每股收益为0.50美元，同比增长2.61%；息税前利润为8.35亿美元，同比下降0.36%。公司未披露分业务营收与同比细分数据，当前看点集中在美国处方渠道覆盖与价格策略的协同带动处方量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Viatris Inc.本季度营收预计增3.77%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517455736","title":"杰富瑞投资银行：维持Viatris(VTRS.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517455736","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517455736?lang=zh_cn&edition=full","pubTime":"2025-03-08 01:22","pubTimestamp":1741368127,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Viatris(VTRS.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至13.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08012248604905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517167691","title":"晖致2024财年实现净利润-6.34亿美元，同比减少1259.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517167691?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276870,"startTime":"0","endTime":"0","summary":"3月7日，晖致公布财报，公告显示公司2024财年净利润为-6.34亿美元，同比减少1259.05%；其中营业收入为147.10亿美元，同比减少4.37%，每股基本收益为-0.53美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000136abeb8d1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000136abeb8d1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658827","title":"巴克莱：维持Viatris(VTRS.US)评级，由减持调整至减持评级, 目标价由12.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658827","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658827?lang=zh_cn&edition=full","pubTime":"2025-03-01 07:04","pubTimestamp":1740783850,"startTime":"0","endTime":"0","summary":"巴克莱：维持Viatris(VTRS.US)评级，由减持调整至减持评级, 目标价由12.00美元调整至9.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01070448470449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105655803","title":"异动解读 | Viatris公司财报低于预期加上FDA限制措施 股价盘中暴跌20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105655803","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105655803?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:49","pubTimestamp":1740667786,"startTime":"0","endTime":"0","summary":"Viatris Inc.公司股价今日盘中暴跌20.73%,引发市场广泛关注。公司股价大幅走低的主要原因来自以下两个方面:. 首先,Viatris公司2024年第四季度的财报数据出现了不尽理想的表现。此外,早些时候美国FDA针对Viatris在印度印多尔的工厂实施进口限制措施,也给公司今年的业务发展带来了不利影响。Viatris预计FDA的行动将减少公司2025年的收入约5亿美元,调整后核心利润也将减少约3.85亿美元。监管部门措施加剧了市场对公司增长前景的担忧,进一步推动了股价的暴跌走势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514854013","title":"晖致盘中异动 股价大跌17.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854013","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514854013?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:30","pubTimestamp":1740666604,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时30分，晖致股票出现异动，股价快速下跌17.62%。截至发稿，该股报9.26美元/股，成交量222.466万股，换手率0.19%，振幅0.00%。晖致股票所在的制药行业中，整体涨幅为0.00%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722300498950f96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722300498950f96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","BK4585","LU1839511570.USD","VTRS","LU2087621335.USD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139205945","title":"异动解读 | Viatris财报营收低于预期引发股价盘前大跌7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139205945","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139205945?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:00","pubTimestamp":1740657635,"startTime":"0","endTime":"0","summary":"Viatris公司股价今日周四盘前交易大跌7.21%,主要受公司发布的2024年第四季度业绩报告拖累。\n\nViatris2024年第四季度财报显示,公司调整后每股收益0.54美元,低于市场预期的0.57美元;营收35.2亿美元,也未达到分析师预期的36.1亿美元。同时,财报显示公司同比去年的营收和每股收益均出现了下滑。\n\n公司业绩不达预期和同比下滑,令投资者对Viatris的盈利前景感到失望和担忧,引发了今日公司股票在盘前交易中大跌的行情。投资人将持续关注Viatris公司是否能在未来实现业绩复苏。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117219132","title":"Viatris 2024年第四季度调整后每股收益$0.54低于预期$0.57，销售额$35.2亿低于预期$36.1亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1117219132","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117219132?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:58","pubTimestamp":1740657527,"startTime":"0","endTime":"0","summary":"Viatris  报告其季度每股收益为$0.54，比分析师一致预期的$0.57低5.26%。与去年同期的销售额$38.3亿相比，下降了8.13%。以上内容来自Benzinga Earnings专栏，原文如下：Viatris  reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.57 by 5.26 percent. This is a 12.9 percent decrease over earnings of $0.62 per share from the same period last year.  The company reported quarterly sales of $3.52 billion which missed the analyst consensus estimate of $3.61 billion by 2.75 percent.  This is a 8.13 percent decrease over sa","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viatris 2024年第四季度调整后每股收益$0.54低于预期$0.57，销售额$35.2亿低于预期$36.1亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2484102005","title":"晖致2024财年第三财季实现净利润94.80百万美元，同比减少71.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484102005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484102005?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:01","pubTimestamp":1731772898,"startTime":"0","endTime":"0","summary":"11月17日，晖致公布财报，公告显示公司2024财年第三财季净利润为94.80百万美元，同比减少71.45%；其中营业收入为37.57亿美元，同比减少4.30%，每股基本收益为0.08美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000235abc78f6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000235abc78f6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142747545","title":"异动解读 | 新药亮眼业绩超预期 Viatris股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142747545","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142747545?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:48","pubTimestamp":1730990923,"startTime":"0","endTime":"0","summary":"制药公司Viatris股价在11月7日盘中大涨5.08%,引发市场关注。公司新鲜出炉的第三季度财报成为推动股价上涨的主因。数据显示,Viatris第三季度营收达37.4亿美元,超过分析师预期的37.1亿美元。Viatris是2020年由默克和辉瑞旗下业务合并组建而成,在品牌药和仿制药两大领域都有版图。除了新产品销售亮眼,公司传统品牌药如伟哥、Xanax等也保持了稳健增长。本季度,其品牌药业务同比增长2%至23.6亿美元,仿制药业务增长4%至13.8亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 新药亮眼业绩超预期 Viatris股价大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481890071","title":"晖致盘中异动 早盘快速上涨5.00%报12.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481890071","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481890071?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:33","pubTimestamp":1730990034,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时33分，晖致股票出现异动，股价快速拉升5.00%。截至发稿，该股报12.19美元/股，成交量53.4534万股，换手率0.04%，振幅3.88%。晖致股票所在的制药行业中，整体涨幅为0.63%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722335498e4131a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722335498e4131a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VTRS","BK4585","LU2087621335.USD","BK4007","LU1839511570.USD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viatris.com;investor.viatris.com","stockEarnings":[{"period":"1week","weight":0.0447},{"period":"1month","weight":0.0943},{"period":"3month","weight":0.0538},{"period":"6month","weight":0.2411},{"period":"1year","weight":0.8257},{"period":"ytd","weight":0.4635}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0383},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1603},{"period":"ytd","weight":0.1318}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viatris Inc.于2019年2月14日在特拉华州成立。该公司是一家全球性的医疗保健公司，该公司认为他们具有独特的定位，可以弥合仿制药和品牌之间的传统鸿沟，将两者的优点结合起来，以更全面地满足全球范围内的医疗保健需求。Viatris的使命是赋能世界各地的人们在生命的每个阶段都能过上更健康的生活，大规模地提供准入服务，目前每年为全球约10亿患者提供高质量的药物，并触及生命的所有时刻，从出生到生命的尽头，从急性病到慢性病。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.024969},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.073864},{"month":3,"riseRate":0,"avgChangeRate":-0.068903},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.014515},{"month":5,"riseRate":0.666667,"avgChangeRate":0.060472},{"month":6,"riseRate":0.5,"avgChangeRate":-0.02049},{"month":7,"riseRate":0.5,"avgChangeRate":0.03071},{"month":8,"riseRate":0.666667,"avgChangeRate":0.032534},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048616},{"month":10,"riseRate":0.5,"avgChangeRate":0.025111},{"month":11,"riseRate":0.8,"avgChangeRate":0.040541},{"month":12,"riseRate":0.833333,"avgChangeRate":0.086301}],"exchange":"NASDAQ","name":"Viatris Inc.","nameEN":"Viatris Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viatris Inc.,VTRS,Viatris Inc.股票,Viatris Inc.股票老虎,Viatris Inc.股票老虎国际,Viatris Inc.行情,Viatris Inc.股票行情,Viatris Inc.股价,Viatris Inc.股市,Viatris Inc.股票价格,Viatris Inc.股票交易,Viatris Inc.股票购买,Viatris Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}